NSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.
Biocon Ltd: key numbers
- Share price
- ₹351.90
- Market cap
- ₹57,349 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 115.8×Sector 48.7×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech
Biocon Legal & Regulatory
Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.
- Value
- ₹3.21 Cr
Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Other employee stock options announcements
All →Cholamandalam Investment & Finance Company Employee Stock Options
Cholamandalam Investment and Finance allotted 1,20,202 equity shares to employees upon the exercise of stock options. The company will now seek listing for these shares.
Mahindra & Mahindra Employee Stock Options
Mahindra & Mahindra transferred equity shares from its ESOP Trust to employees upon exercise of stock options. This is a routine employee benefit disclosure.
JSW Energy Employee Stock Options
JSW Energy's employee welfare trust transferred 10,044 shares to employees after ESOP option exercises. The off-market transfer was valued at about Rs 0.01 Crore.
- Value
- ₹0.01 Cr
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Raymond Employee Stock Options
Raymond allotted 1,56,784 equity shares to its ESOP Trust under the Raymond Employees Stock Option Plan 2023. Paid-up capital rose to Rs. 66,73,05,150.
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.